T. Rowe Price Associates
IMDZ

T. Rowe Price Associates’s Immune Design Corp. IMDZ Stock Holding History

T. Rowe Price Associates’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-35,252
Closed -$122K – 2652
2018
Q3 		$122K Buy
35,252
+207
+0.6% +$777 ﹤0.01% 2517
2018
Q2 		$159K Buy
35,045
+35
+0.1% +$139 ﹤0.01% 2487
2018
Q1 		$116K Buy
35,010
+62
+0.2% +$219 ﹤0.01% 2491
2017
Q4 		$136K Buy
+34,948
New +$190K ﹤0.01% 2478
2016
Q1 		– Sell
-327,432
Closed -$6.58M – 2589
2015
Q4 		$6.58M Sell
327,432
-785,377
-71% -$13.5M ﹤0.01% 1374
2015
Q3 		$13.6M Sell
1,112,809
-15,232
-1% -$285K ﹤0.01% 1226
2015
Q2 		$23.3M Buy
1,128,041
+426,000
+61% +$10.1M ﹤0.01% 1084
2015
Q1 		$14.8M Sell
702,041
-47,100
-6% -$1.23M ﹤0.01% 1217
2014
Q4 		$23.1M Buy
749,141
+8,900
+1% +$247K ﹤0.01% 1076
2014
Q3 		$13.1M Buy
+740,241
New +$9.37M ﹤0.01% 1232

Other funds holding IMDZ

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates's IMDZ Position: Q4 2018 in Review

T. Rowe Price Associates sold out of Immune Design Corp. (IMDZ) in Q4 2018, closing a stake of 35,252 shares — an estimated $122K sold.

T. Rowe Price Associates first reported a position in IMDZ in Q3 2014 and held it in 10 quarters. The position peaked at $23.3M in Q2 2015. 64 funds tracked by Wall St. Rank hold IMDZ as of Q4 2018.

  • T. Rowe Price Associates reported no remaining Immune Design Corp. position as of Q4 2018 after selling out during the quarter.
  • T. Rowe Price Associates sold 35,252 Immune Design Corp. shares in Q4 2018, an estimated $122K.
  • T. Rowe Price Associates first reported a position in Immune Design Corp. in Q3 2014 and held it in 10 quarters.
  • T. Rowe Price Associates's Immune Design Corp. position peaked at $23.3M in Q2 2015.
  • 64 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2018.

Based on T. Rowe Price Associates's 13F filing for Q4 2018, filed 14 Feb 2019.